Suchen
Lantern Pharma Inc
LTRNZur Watchlist hinzufügen
3.970USD
-0.050-1.24%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
44.68MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lantern Pharma Inc Unternehmen
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Lantern Pharma Inc Informationen
BörsenkürzelLTRN
Name des UnternehmensLantern Pharma Inc
IPO-datumJun 11, 2020
CEOSharma (Panna L)
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeJun 11
Addresse1920 Mckinney Avenue
StadtDALLAS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl75201
Telefon19722771136
Websitehttps://www.lanternpharma.com/
BörsenkürzelLTRN
IPO-datumJun 11, 2020
CEOSharma (Panna L)
Führungskräfte von Lantern Pharma Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Lantern Pharma Inc?
Die fünf größten Anteilseigner von Lantern Pharma Inc sind: Mr. Panna L. Sharma
Wie viele Institutionen halten Anteile an Lantern Pharma Inc (LTRN)?
Mit Stand vom 2026Q1 halten 78 Institutionen Anteile an Lantern Pharma Inc, mit einem Gesamtmarktwert von etwa 2.65M, was 23.45% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 119203.00 gestiegen.